ArticleCA: a cancer journal for clinicians
Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: A National Lung Cancer Roundtable best-practice guide.
Article in CA: a cancer journal for clinicians. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 35 citations in OpenAlex.
- AKT Inhibitor Capivasertib as a Target for Osimertinib Combination Therapy in Lung Adenocarcinoma withGenes · 2026Article
- Review
- Commercial price variation in precision oncology testing across US hospitals.Health affairs scholar · 2026Article
- Review
- FOXM1-associated melanoma stratification: integrated multi-omics and experimental validation reveal prognostic significance and therapeutic potential.BMC cancer · 2026Article
- HER2 Alterations in Squamous Cell Lung Cancer: Biology, Therapeutic Landscape, and Emerging Precision Approaches.Cancers · 2026Review
- Quantum dot-DNA microsphere aptamer biosensor with AI-assisted structural modeling for rapid detection of the lung cancer biomarker USE1.Journal of nanobiotechnology · 2026Article
- Multidisciplinary international expert consensus recommendations on tissue acquisition in non-small cell lung cancer.EBioMedicine · 2026Article
- Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer usingJournal of translational medicine · 2026Article
- Concordance study of bronchial biopsy tissues and matched bronchial brushing cytology specimens in driver gene detection of non-small cell lung cancer.Frontiers in oncology · 2026Article
- Mismatch-introduced crRNA guided PCR-CRISPR/Cas12a platform improves EGFR point mutation detection in single tumor cell.Mikrochimica acta · 2025Article
- The Landmark Series: Advances in Preoperative Mediastinal Lymph Node Staging for Non-small Cell Lung Cancer (NSCLC).Annals of surgical oncology · 2025Review
- Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations.The oncologist · 2025Review
- Lung Cancer Therapy: The Role of Personalized Medicine.Cancers · 2025Review
- Exosomes in early lung cancer diagnostics: the current state of progress made and prospects.Frontiers in cell and developmental biology · 2025Review
- Bioinformatics Analysis of Key Genes Associated with Resistance to the Combination of Bevacizumab and Pemetrexed Chemotherapy in Non-small Cell Lung Cancer.Recent patents on anti-cancer drug discovery · 2025Article
- Transforming Lung Cancer Care: The Role of Transferosomes in Modern Drug Delivery.Current cancer drug targets · 2025Review
- Pulmonologists' Attitudes and Role in Precision Medicine Biomarker Testing for Non-Small Cell Lung Cancer.Chest · 2024Article
- Neutrophil-targeted liposomal platform: A shift in novel approach for early detection and treatment of cancer metastasis.Asian journal of pharmaceutical sciences · 2024Article
- Mixed Methods Evaluation of Gaps and Barriers in Delivery of Precision Oncology in Advanced Lung Cancer.Journal of oncology navigation & survivorship · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 7 institutions in 1 country.
Funding
Abstract
Advances in biomarker-driven therapies for patients with nonsmall cell lung cancer (NSCLC) both provide opportunities to improve the treatment (and thus outcomes) for patients and pose new challenges for equitable care delivery. Over the last decade, the continuing development of new biomarker-driven therapies and evolving indications for their use have intensified the importance of interdisciplinary communication and coordination for patients with or suspected to have lung cancer. Multidisciplinary teams are challenged with completing comprehensive and timely biomarker testing and navigating the constantly evolving evidence base for a complex and time-sensitive disease. This guide provides context for the current state of comprehensive biomarker testing for NSCLC, reviews how biomarker testing integrates within the diagnostic continuum for patients, and illustrates best practices and common pitfalls that influence the success and timeliness of biomarker testing using a series of case scenarios.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.